 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: The KEYNOTE-158 study shows that pembrolizumab (pembrolizumab) has a significant effect in the treatment of MSI-H/dMMR endometrial cancer patients

J Clin Oncol: The KEYNOTE-158 study shows that pembrolizumab (pembrolizumab) has a significant effect in the treatment of MSI-H/dMMR endometrial cancer patients

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

nci comprehensive cancer centers

study climate change

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

KEYNOTE-158 is an open-label, multi-cohort, phase II study evaluating pembrolizumab in patients with multiple types of advanced solid tumors
.

Recently, the Journal of Clinical Oncology published the efficacy and safety of PD-1 inhibitor Pembrolizumab (pembrolizumab) in previously treated MSI-H/dMMR endometrial cancer patients in the KEYNOTE-158 study

KEYNOTE-158 is an open-label, multi-cohort, phase II study evaluating pembrolizumab in patients with multiple types of advanced solid tumors

From cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumor,Patients with previously treated advanced MSI-H/dMMR endometrial cancer (except colorectal cancer ) received pembrolizumab 200 mg every 3 weeks for 35 cycles
.

The primary endpoint was objective response rate as assessed by independent radiology centers

As of October 5, 2020, of the 90 treated patients, 18 (20%) had completed 35 cycles of pembrolizumab and 52 (58%) had discontinued treatment

Among 79 patients evaluable for response, the objective response rate was 48% (95% CI, 37 - 60), including 11 (14%) CR and 27 (34%) PR

Efficacy assessment

Median progression-free survival was 13.
1 months (95% CI, 4.
3 to 34.
4), and Kaplan-Meier estimated PFS rates were 51% at 1 year, 41% at 2 years, and 37% at 3 and 4 years
.

Median overall survival was not reached (95% CI, 27.

Median progression-free survival was 13.

PFS and OS

PFS and OSPFS and OS

Among all treated patients, 76% experienced ≥1 treatment-related adverse event (Grades 3-4, 12%)
.

There were no fatal treatment-related events

Among all treated patients, 76% experienced ≥1 treatment-related adverse event (Grades 3-4, 12%)

TRAE

In conclusion, the KEYNOTE-158 study shows that Pembrolizumab (pembrolizumab) is effective and safe and controllable in the treatment of MSI-H/dMMR endometrial cancer patients
.

The KEYNOTE-158 study shows that Pembrolizumab (pembrolizumab) has a significant effect and is safe and controllable in the treatment of MSI-H/dMMR endometrial cancer patients

Original source:

O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M.
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
J Clin Oncol.
2022 Jan 6:JCO2101874.
doi: 10.
1200/JCO.
21.
01874.
Epub ahead of print.
PMID: 34990208.
Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
J Clin Oncol.
2022 Jan 6:JCO2101874.
doi: 10.
1200/JCO.
21.
01874.
Epub ahead of print.
PMID: 34990208.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.